Robert J. Spiegel

CIK: 0001492256

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)18 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RNXT

RenovoRx, Inc.

Director

GERN

GERON CORP

Director

ERNA

Ernexa Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (18 total)

RNXT
RenovoRx, Inc.
Oct 1, 2026
Award(A)
Stock Options (right to buy)
Direct
55.9K shares-
GERN
GERON CORP
Sep 30, 2026
Award(A)
Direct
6.4K shares at avg. $1.23$8K
GERN
GERON CORP
Jun 30, 2026
Award(A)
Direct
6.1K shares at avg. $1.28$8K
GERN
GERON CORP
May 20, 2026
Award(A)
Stock Option (right to buy)
Direct
220K shares-
GERN
GERON CORP
Mar 31, 2026
Award(A)
Direct
5.2K shares at avg. $1.49$8K
GERN
GERON CORP
Dec 31, 2025
Award(A)
Direct
5.9K shares at avg. $1.32$8K
RNXT
RenovoRx, Inc.
Oct 1, 2025
Award(A)
Stock Options (right to buy)
Direct
47.6K shares-
GERN
GERON CORP
Sep 30, 2025
Award(A)
Direct
5.7K shares at avg. $1.37$8K
GERN
GERON CORP
Jun 30, 2025
Award(A)
Direct
5.5K shares at avg. $1.41$8K
GERN
GERON CORP
May 21, 2025
Award(A)
Stock Option (right to buy)
Direct
180K shares-
GERN
GERON CORP
Mar 31, 2025
Award(A)
Direct
4.9K shares at avg. $1.59$8K
GERN
GERON CORP
Dec 31, 2024
Award(A)
Direct
2.2K shares at avg. $3.54$8K
GERN
GERON CORP
Dec 31, 2024
Award(A)
Direct
2.2K shares-
RNXT
RenovoRx, Inc.
Oct 1, 2024
Award(A)
Stock Options (right to buy)
Direct
25.1K shares-
GERN
GERON CORP
Sep 30, 2024
Award(A)
Direct
1.8K shares at avg. $4.54$8K
GERN
GERON CORP
Sep 30, 2024
Award(A)
Direct
1.8K shares-
GERN
GERON CORP
Jun 28, 2024
Award(A)
Direct
1.9K shares at avg. $4.24$8K
GERN
GERON CORP
Mar 29, 2024
Award(A)
Direct
2.5K shares at avg. $3.30$8K

		Type	Shares	Price		Ownership
Oct 1, 2026	RNXT RenovoRx, Inc.	Award(A) Stock Options (right to buy)	55,924	-	-	Direct
Sep 30, 2026	GERN GERON CORP	Award(A)	6,351	$1.23	$7,812	Direct
Jun 30, 2026	GERN GERON CORP	Award(A)	6,103	$1.28	$7,812	Direct
May 20, 2026	GERN GERON CORP	Award(A) Stock Option (right to buy)	220,000	-	-	Direct
Mar 31, 2026	GERN GERON CORP	Award(A)	5,243	$1.49	$7,812	Direct
Dec 31, 2025	GERN GERON CORP	Award(A)	5,918	$1.32	$7,812	Direct
Oct 1, 2025	RNXT RenovoRx, Inc.	Award(A) Stock Options (right to buy)	47,640	-	-	Direct
Sep 30, 2025	GERN GERON CORP	Award(A)	5,702	$1.37	$7,812	Direct
Jun 30, 2025	GERN GERON CORP	Award(A)	5,540	$1.41	$7,811	Direct
May 21, 2025	GERN GERON CORP	Award(A) Stock Option (right to buy)	180,000	-	-	Direct
Mar 31, 2025	GERN GERON CORP	Award(A)	4,913	$1.59	$7,812	Direct
Dec 31, 2024	GERN GERON CORP	Award(A)	2,206	$3.54	$7,809	Direct
Dec 31, 2024	GERN GERON CORP	Award(A)	2,206	-	$0	Direct
Oct 1, 2024	RNXT RenovoRx, Inc.	Award(A) Stock Options (right to buy)	25,099	-	-	Direct
Sep 30, 2024	GERN GERON CORP	Award(A)	1,767	$4.54	$8,022	Direct
Sep 30, 2024	GERN GERON CORP	Award(A)	1,767	-	$0	Direct
Jun 28, 2024	GERN GERON CORP	Award(A)	1,916	$4.24	$8,124	Direct
Mar 29, 2024	GERN GERON CORP	Award(A)	2,462	$3.30	$8,125	Direct

1-18 of 18 transactions

About Spiegel Robert J.

Spiegel Robert J. (SEC CIK 0001492256) files insider reports with the SEC as Director of RenovoRx, Inc. (RNXT), Director of GERON CORP (GERN) and Director of Ernexa Therapeutics Inc. (ERNA).

Signal8 holds 18 ownership filings by Spiegel Robert J. (1 Form 3, 17 Form 4), filed between Oct 1, 2024 and Oct 2, 2026. Those filings report 18 transactions, from Mar 29, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Spiegel Robert J.'s filings is in FOSTER CITY, CA.

Recent filings by Spiegel Robert J.

Oct 1, 2026: Grant or award of RNXT derivative securities (Form 4, code A).
Sep 30, 2026: Grant or award of GERN shares (Form 4, code A).
Jun 30, 2026: Grant or award of GERN shares (Form 4, code A).
May 20, 2026: Grant or award of GERN derivative securities (Form 4, code A).
Mar 31, 2026: Grant or award of GERN shares (Form 4, code A).

Other insiders filing for RenovoRx, Inc. (RNXT)

Macfarlane K. Angela, Director
RYAN UNA S, Director
Marton Laurence, Director
VOLL MARK, Chief Financial Officer
Bagai Shaun, Chief Executive Officer
Gentry Leesa, Chief Clinical Officer

How to read Form 4 transaction codes